Sellas Life Sciences Group, Inc. · NASDAQ:SLS
Sellas Life Sciences — Investor Symposium on Galinpepimut-S (August 2021)
20 slides from Sellas Life Sciences's conference presentation, Aug 17, 2021
Slide 1: Investor Symposium on Galinpepimut-S
NASDAQ: SLS Investor Symposium on Galinpepimut-S August 17, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. Such forward-looking statements can be identified by the use of the words “expect,” “believe,” “will,” “anticipate,” “estimate,” “plan,” “project” and other words of similar import. The forward-looking statements in th
Slide 3: Agenda
Agenda Time (ET) Topic Presenter Angelos Stergiou, M.D., SC.D. H.C. 1:00pm – 1:05pm Welcome & Introduction to Galinpepimut-S (GPS) President & Chief Executive Officer, SELLAS M. Yair Levy, M.D. AML: Landscape, Treatment Modalities and 1:05pm – 1:20pm Director of Hematologic Malignancies, Baylor Univ
Slide 4: Welcome & Introduction to GPS
Welcome & Introduction to GPS Angelos Stergiou, M.D., SC.D. H.C. President & Chief Executive Officer, SELLAS Life Sciences
Slide 5: AML: Landscape, Treatment Modalities and Challenges/Opportunities
AML: Landscape, Treatment Modalities and Challenges/Opportunities M. Yair Levy, M.D. Director of Hematologic Malignancies, Baylor University Medical Center
Slide 6: Acute Myeloid Leukemia (AML): Landscape, Treatment Modalities and Challenges/Opportunities
Acute Myeloid Leukemia (AML): Landscape, Treatment Modalities and Challenges/Opportunities § Treatment of acute myeloid leukemia is rapidly evolving § Primary goal of AML therapy is to cure patients , and curative therapy most often requires bone marrow transplant § Big advances made in bone marrow
Slide 7: Galinpepimut-S: Technology
Galinpepimut-S: Technology Dragan Cicic, M.D. Senior Vice President, Clinical Development, SELLAS Life Sciences
Slide 8: Wilms Tumor-1 (WT1) Protein: A Top Priority Target in Cancer
Wilms Tumor-1 (WT1) Protein: A Top Priority Target in Cancer • WT1 is a nuclear transcription factor with oncogenic properties, which is broadly detectable in AML (where it is densely and almost universally expressed)1 • WT1 not found appreciably in adult tissues, which lowers potential off- target
Slide 9: GPS: Uniquely Differentiated Peptide Vaccine Discovered at MSKCC
GPS: Uniquely Differentiated Peptide Vaccine Discovered at Memorial Sloan Kettering Cancer Center (MSKCC) IO: Immuno-Oncology Pinilla-Ibarz, Leukemia. 2006; Gomez-Nunez, Leuk Res. 2006; May, Clin Cancer Res. 2007; Maslak, Blood. 2010; Krug, Cancer Immunol Immunother. 2010 9
Slide 10: Compelling Survival Benefit Seen in AML Patients in CR2
Compelling Survival Benefit Seen in AML Patients in CR2 1,2 Completed Phase 2 Open-label Study in Acute Myeloid Leukemia (AML) Patients Who Achieve Second Complete Remission (CR2) at Moffitt Cancer Center (MCC) Median Overall Survival (All Age Patients):GPS vs SOC* Relapse Free Survival (All Age Pat
Slide 11: Further Validation of GPS Efficacy of AML: CR1 Phase 2 Study
Further Validation of GPS Efficacy of AML: CR1 Phase 2 Study Phase 2 Open-label Clinical Study in AML Patients Who Achieve First Complete Remission (CR1) Overall Survival (OS) (All Age Patients):GPS vs SOC 67.6 months vs 17.5 - 25 months OS ( >60 Years Patients ):GPS vs SOC 35.5 months vs 12 - 14.5
Slide 12: Design of Phase 3 Registration Study in CR2 AML Patients (REGAL)
Design of Phase 3 Registration Study in CR2 AML Patients (REGAL) Target Population and Treatment: Endpoints and Interim Inclusion Criteria Open Label; Randomised Multi-center Phase 3 Trial Analysis N = 116 Patients >18 years old Cohort 1 GPS: 800 µg of peptide mixture; 200 µg of each peptide/dose Pr
Slide 13: AML Treatment Algorithm By Patient Type
AML Treatment Algorithm By Patient Type No actionable mutations (FLT3, IDH 1/2) Actionable mutations (FLT3, IDH 1/2) Newly diagnosed < 75 y, good shape > 75 y, frail < 75 y, good shape > 75 y, frail First Line Tx 3+7 VCom 3+7+ IDH1/2/FLT3 IDH1/2/FLT3 Vyxeos for sAML Followed by: VCom for adverse SCT
Slide 14: GPS in REGAL Trial Addresses Needs of Most Relapsed Patients
GPS in REGAL Trial Addresses Needs of Most Relapsed Patients Relapsed AML Patients < 75 y, good shape > 75 y, frail Intensive Therapy Less Intensive Therapy Response Response ~70-85% no transplant Bone Marrow No BMT Less Intensive Maintenance Transplant (BMT) ~60% severe toxicity REGAL Trial No Seve
Slide 15: New Data Highlight Opportunities in Bone Marrow Transplant Settings
New Data Highlight Opportunities in Bone Marrow Transplant Settings Probability CR1/MRD+ Median OS post – AlloSCT estimate: ~26 months Median OS post GPS estimate in similar unselected patients: ~48.5 months Percival M-E, et al. Bone Marrow Transplant., 2021 CR1 Ph2 Study; Maslak, 2018 Time post-tra
Slide 16: GPS Patient Population Expansion
GPS Patient Population Expansion Newly Diagnosed AML Patients < 75 y, good shape > 75 y, frail Intensive Therapy Less Intensive Therapy Response Response Additional BMT Additional Less Intensive Maintenance No BMT GPS Patients GPS Patients Additional No Severe Toxicity Severe Toxicity GPS Patients R
Slide 17: GPS-Pembrolizumab Clinical Program Update
GPS-Pembrolizumab Clinical Program Update • 11 advanced ovarian cancer patients received at least three doses of GPS to date, the last of which in combination with pembrolizumab • Patient population • All enrolled patients (100%) resistant to standard of care platinum based therapy • 66.7% of evalua
Slide 18: GPS-Nivolumab Clinical Program Update
GPS-Nivolumab Clinical Program Update • 4 evaluable patients received GPS plus nivolumab for at least one month • Patient population • All enrolled patients were resistant to standard of care pemetrexed based therapy • Overall Survival • Median overall survival among the patients in this trial was 3
Slide 19: GPS Clinical Development Summary
GPS Clinical Development Summary • Strong and independently validated vaccine technology • Five completed clinical trials with compelling efficacy results in overall survival across different cancer indications • Very low toxicity • Three ongoing clinical trials • Pivotal Phase 3 trial in acute myel
Slide 20: Q&A Session
Q&A Session ANGELOS M. STERGIOU, M.D., SC.D. H.C. DRAGAN CICIC, MD President & Chief Executive Officer Senior Vice President, Clinical Development SELLAS Life Sciences SELLAS Life Sciences M. YAIR LEVY, M.D. Director of Hematologic Malignancies Baylor University Medical Center 20
SELLAS Life Sciences Group — Investor Symposium on Galinpepimut-S (August 2021) on 6ix